Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

Dementia care during COVID-19.

Wang H, Li T, Barbarino P, Gauthier S, Brodaty H, Molinuevo JL, Xie H, Sun Y, Yu E, Tang Y, Weidner W, Yu X.

Lancet. 2020 Mar 30. pii: S0140-6736(20)30755-8. doi: 10.1016/S0140-6736(20)30755-8. [Epub ahead of print] No abstract available.

PMID:
32240625
2.

NeAT: a Nonlinear Analysis Toolbox for Neuroimaging.

Casamitjana A, Vilaplana V, Puch S, Aduriz A, López C, Operto G, Cacciaglia R, Falcón C, Molinuevo JL, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative.

Neuroinformatics. 2020 Mar 24. doi: 10.1007/s12021-020-09456-w. [Epub ahead of print]

PMID:
32212063
3.

APOE-ε4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks.

Cacciaglia R, Molinuevo JL, Falcón C, Arenaza-Urquijo EM, Sánchez-Benavides G, Brugulat-Serrat A, Blennow K, Zetterberg H, Gispert JD; ALFA study.

Cereb Cortex. 2020 Mar 12. pii: bhaa034. doi: 10.1093/cercor/bhaa034. [Epub ahead of print]

PMID:
32163130
4.

Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.

Skouras S, Torner J, Andersson P, Koush Y, Falcon C, Minguillon C, Fauria K, Alpiste F, Blenow K, Zetterberg H, Gispert JD, Molinuevo JL; ALFA Study .

Brain. 2020 Mar 1;143(3):976-992. doi: 10.1093/brain/awaa011.

5.

CSF cutoffs for MCI due to AD depend on APOEε4 carrier status.

Marizzoni M, Ferrari C, Babiloni C, Albani D, Barkhof F, Cavaliere L, Didic M, Forloni G, Fusco F, Galluzzi S, Hensch T, Jovicich J, Marra C, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Ranjeva JP, Ribaldi F, Rolandi E, Rossini PM, Salvatore M, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB.

Neurobiol Aging. 2020 May;89:55-62. doi: 10.1016/j.neurobiolaging.2019.12.019. Epub 2019 Dec 30.

PMID:
32029236
6.

The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0.

Ritchie CW, Muniz-Terrera G, Kivipelto M, Solomon A, Tom B, Molinuevo JL.

J Prev Alzheimers Dis. 2020;7(1):8-13. doi: 10.14283/jpad.2019.46.

PMID:
32010920
7.

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort.

Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Baker S, Buckley NJ, Ten Kate M, Scheltens P, Teunissen CE, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lléo A, Sala I, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Legido-Quigley C, Bertram L, Barkhof F, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Lovestone S.

J Alzheimers Dis. 2020;74(1):213-225. doi: 10.3233/JAD-190434.

PMID:
31985466
8.

The characterisation of subjective cognitive decline.

Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, Rabin L, Rentz DM, Rodriguez-Gomez O, Saykin AJ, Sikkes SAM, Smart CM, Wolfsgruber S, Wagner M.

Lancet Neurol. 2020 Mar;19(3):271-278. doi: 10.1016/S1474-4422(19)30368-0. Epub 2020 Jan 17. Review.

PMID:
31958406
9.

Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings.

Vermunt L, Muniz-Terrera G, Ter Meulen L, Veal C, Blennow K, Campbell A, Carrié I, Delrieu J, Fauria K, Huesa Rodríguez G, Ingala S, Jenkins N, Molinuevo JL, Ousset PJ, Porteous D, Prins ND, Solomon A, Tom BD, Zetterberg H, Zwan M, Ritchie CW, Scheltens P, Luscan G, Brookes AJ, Visser PJ; IMI-EPAD collaborators.

Alzheimers Res Ther. 2020 Jan 6;12(1):8. doi: 10.1186/s13195-019-0576-y.

10.

Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults.

Grau-Rivera O, Operto G, Falcón C, Sánchez-Benavides G, Cacciaglia R, Brugulat-Serrat A, Gramunt N, Salvadó G, Suárez-Calvet M, Minguillon C, Iranzo Á, Gispert JD, Molinuevo JL; ALFA Study.

Alzheimers Res Ther. 2020 Jan 7;12(1):4. doi: 10.1186/s13195-019-0547-3.

11.

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease.

Milà-Alomà M, Suárez-Calvet M, Molinuevo JL.

Ther Adv Neurol Disord. 2019 Dec 18;12:1756286419888819. doi: 10.1177/1756286419888819. eCollection 2019. Review.

12.

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort.

Stamate D, Kim M, Proitsi P, Westwood S, Baird A, Nevado-Holgado A, Hye A, Bos I, Vos SJB, Vandenberghe R, Teunissen CE, Kate MT, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Engelborghs S, Sleegers K, Bordet R, Ramit L, Kettunen P, Tsolaki M, Verhey F, Alcolea D, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement (N Y). 2019 Dec 18;5:933-938. doi: 10.1016/j.trci.2019.11.001. eCollection 2019.

13.

Physical activity is associated with better global cognition and frontal function in overweight/obese older adults with metabolic syndrome.

Coll-Padrós N, León M, Valech N, Ros E, Vidal J, Estruch R, Fitó M, Salas-Salvadó J, Corella D, Molinuevo JL, Rami L.

Eur Rev Aging Phys Act. 2019 Dec 6;16:23. doi: 10.1186/s11556-019-0229-y. eCollection 2019.

14.

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

Ashton NJ, Suárez-Calvet M, Heslegrave A, Hye A, Razquin C, Pastor P, Sanchez-Valle R, Molinuevo JL, Visser PJ, Blennow K, Hodges AK, Zetterberg H.

Alzheimers Res Ther. 2019 Nov 28;11(1):94. doi: 10.1186/s13195-019-0545-5.

15.

White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants.

Brugulat-Serrat A, Salvadó G, Operto G, Cacciaglia R, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Minguillon C, Fauria K, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Hum Brain Mapp. 2020 Apr 1;41(5):1309-1322. doi: 10.1002/hbm.24877. Epub 2019 Nov 28.

PMID:
31778002
16.

Plant-Rich Dietary Patterns, Plant Foods and Nutrients, and Telomere Length.

Crous-Bou M, Molinuevo JL, Sala-Vila A.

Adv Nutr. 2019 Nov 1;10(Suppl_4):S296-S303. doi: 10.1093/advances/nmz026.

PMID:
31728493
17.

Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid-β Levels.

Valech N, Sánchez-Benavides G, Tort-Merino A, Coll-Padrós N, Olives J, León M, Falcon C, Molinuevo JL, Rami L.

J Alzheimers Dis. 2019;72(4):1287-1302. doi: 10.3233/JAD-190624.

PMID:
31707366
18.

Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.

Antonell A, Tort-Merino A, Ríos J, Balasa M, Borrego-Écija S, Auge JM, Muñoz-García C, Bosch B, Falgàs N, Rami L, Ramos-Campoy O, Blennow K, Zetterberg H, Molinuevo JL, Lladó A, Sánchez-Valle R.

Alzheimers Dement. 2020 Feb;16(2):262-272. doi: 10.1016/j.jalz.2019.09.001. Epub 2020 Jan 6.

PMID:
31668967
19.

Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study.

Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, Tacik P, Namasivayam AA, Mangone G, Schneider R, Latz E, Wüllner U, Svenningsson P, Sánchez-Valle R, Molinuevo JL, Corvol JC, Heneka MT; AETIONOMY study group.

Alzheimers Dement. 2020 Feb;16(2):292-304. doi: 10.1016/j.jalz.2019.07.018. Epub 2020 Jan 6.

20.

Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity.

Mollica MA, Tort-Merino A, Navarra J, Fernández-Prieto I, Valech N, Olives J, León M, Lleó A, Martínez-Lage P, Sánchez-Valle R, Molinuevo JL, Rami L.

Cortex. 2019 Dec;121:117-124. doi: 10.1016/j.cortex.2019.07.021. Epub 2019 Aug 30.

PMID:
31561128
21.

Re-aligning scientific and lay narratives of Alzheimer's disease.

Frisoni GB, Ritchie C, Carrera E, Nilsson P, Ousset PJ, Molinuevo JL, Dubois B, Scheltens P, Minoshima S.

Lancet Neurol. 2019 Oct;18(10):918-919. doi: 10.1016/S1474-4422(19)30323-0. No abstract available.

PMID:
31526751
22.

Interactive effect of age and APOE-ε4 allele load on white matter myelin content in cognitively normal middle-aged subjects.

Operto G, Molinuevo JL, Cacciaglia R, Falcon C, Brugulat-Serrat A, Suárez-Calvet M, Grau-Rivera O, Bargalló N, Morán S, Esteller M; ALFA Study, Gispert JD.

Neuroimage Clin. 2019;24:101983. doi: 10.1016/j.nicl.2019.101983. Epub 2019 Aug 16.

23.

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F, Hong S, Franke A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, Buckley NJ, Kate MT, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Bordet R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleó A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frölich L, Legido-Quigley C, Barkhof F, Blennow K, Zetterberg H, Baker S, Morgan BP, Streffer J, Visser PJ, Bertram L, Lovestone S, Nevado-Holgado AJ.

Alzheimers Dement. 2019 Nov;15(11):1478-1488. doi: 10.1016/j.jalz.2019.06.4951. Epub 2019 Sep 5.

24.

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.

Bertens D, Vos S, Kehoe P, Wolf H, Nobili F, Mendonça A, van Rossum I, Hort J, Molinuevo JL, Heneka M, Petersen R, Scheltens P, Visser PJ.

Alzheimers Res Ther. 2019 Aug 22;11(1):74. doi: 10.1186/s13195-019-0525-9.

25.

Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI.

Petrone PM, Casamitjana A, Falcon C, Artigues M, Operto G, Cacciaglia R, Molinuevo JL, Vilaplana V, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Aug 17;11(1):72. doi: 10.1186/s13195-019-0526-8.

26.

The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, Bradley J, Budde J, Ibanez L, Fernandez MV, Blennow K, Zetterberg H, Heslegrave A, Johansson PM, Svensson J, Nellgård B, Lleo A, Alcolea D, Clarimon J, Rami L, Molinuevo JL, Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Ewers M, Harari O, Haass C, Brett TJ, Benitez BA, Karch CM, Piccio L, Cruchaga C.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaau2291. doi: 10.1126/scitranslmed.aau2291.

PMID:
31413141
27.

Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease: A Predictive Study.

Casamitjana A, Petrone P, Molinuevo JL, Gispert JD, Vilaplana V.

IEEE J Biomed Health Inform. 2020 Feb;24(2):365-376. doi: 10.1109/JBHI.2019.2932565. Epub 2019 Aug 1.

PMID:
31380776
28.

Multipurpose Virtual Reality Environment for Biomedical and Health Applications.

Torner J, Skouras S, Molinuevo JL, Gispert JD, Alpiste F.

IEEE Trans Neural Syst Rehabil Eng. 2019 Aug;27(8):1511-1520. doi: 10.1109/TNSRE.2019.2926786. Epub 2019 Jul 4.

PMID:
31283482
29.

Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals.

Brugulat-Serrat A, Salvadó G, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Sánchez-Benavides G, Gramunt N, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Brain Imaging Behav. 2019 Jul 5. doi: 10.1007/s11682-019-00151-2. [Epub ahead of print]

PMID:
31278650
30.

Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders.

El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, Karran M, Molinuevo JL, Norton M, Atri A.

J Alzheimers Dis. 2019;70(2):323-341. doi: 10.3233/JAD-190426. Review.

31.

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease.

Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, Tariot PN, Raket LL.

Alzheimers Dement (N Y). 2019 May 20;5:164-174. doi: 10.1016/j.trci.2019.04.001. eCollection 2019.

32.

Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels.

Tort-Merino A, Olives J, León M, Peñaloza C, Valech N, Santos-Santos MA, Càmara E, Grönholm-Nyman P, Martínez-Lage P, Fortea J, Molinuevo JL, Sánchez-Valle R, Laine M, Rodríguez-Fornells A, Rami L.

J Alzheimers Dis. 2019;70(1):211-225. doi: 10.3233/JAD-190046.

PMID:
31177219
33.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.

Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8.

34.

Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.

Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B.

J Prev Alzheimers Dis. 2019;6(3):157-163. doi: 10.14283/jpad.2019.14.

PMID:
31062825
35.

Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

36.

APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals.

Cacciaglia R, Molinuevo JL, Falcón C, Sánchez-Benavides G, Gramunt N, Brugulat-Serrat A, Esteller M, Morán S, Fauria K, Gispert JD; ALFA study.

Neuroimage Clin. 2019;23:101818. doi: 10.1016/j.nicl.2019.101818. Epub 2019 Apr 8.

37.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

38.

CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.

Falcon C, Monté-Rubio GC, Grau-Rivera O, Suárez-Calvet M, Sánchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019;23:101801. doi: 10.1016/j.nicl.2019.101801. Epub 2019 Apr 1.

39.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
40.

Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.

Marizzoni M, Ferrari C, Macis A, Jovicich J, Albani D, Babiloni C, Cavaliere L, Didic M, Forloni G, Galluzzi S, Hoffmann KT, Molinuevo JL, Nobili F, Parnetti L, Payoux P, Pizzini F, Rossini PM, Salvatore M, Schönknecht P, Soricelli A, Del Percio C, Hensch T, Hegerl U, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB; PharmaCog Consortium.

J Alzheimers Dis. 2019;69(1):49-58. doi: 10.3233/JAD-181016.

PMID:
30958351
41.

Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.

Skouras S, Falcon C, Tucholka A, Rami L, Sanchez-Valle R, Lladó A, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019;22:101777. doi: 10.1016/j.nicl.2019.101777. Epub 2019 Mar 12.

42.

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, Pavia J, Niñerola-Baizán A, Perissinotti A, Lomeña F, Minguillon C, Fauria K, Zetterberg H, Blennow K, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study.

Alzheimers Res Ther. 2019 Mar 21;11(1):27. doi: 10.1186/s13195-019-0478-z.

43.

Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?

Farrar G, Molinuevo JL, Zanette M.

Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1299-1308. doi: 10.1007/s00259-019-04282-y. Epub 2019 Mar 13.

44.

European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol.

Solomon A, Kivipelto M, Molinuevo JL, Tom B, Ritchie CW; EPAD Consortium.

BMJ Open. 2019 Feb 19;8(12):e021017. doi: 10.1136/bmjopen-2017-021017.

45.

Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort.

Salvadó G, Brugulat-Serrat A, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Alzheimers Res Ther. 2019 Jan 24;11(1):12. doi: 10.1186/s13195-018-0460-1.

46.

Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.

Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padrós N, Bouwman FH, Slot RER, Wesselman LMP, Peters O, Luther K, Buerger K, Priller J, Laske C, Teipel S, Spottke A, Heneka MT, Düzel E, Drzezga A, Wiltfang J, Sikkes SAM, van der Flier WM, Jessen F; Euro-SCD working group.

Alzheimers Res Ther. 2019 Jan 17;11(1):8. doi: 10.1186/s13195-018-0463-y.

47.

"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".

Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R.

Alzheimers Dement. 2019 Jan;15(1):153-157. doi: 10.1016/j.jalz.2018.11.002. No abstract available.

PMID:
30642435
48.

Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease.

Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Geist MA, Raket LL, Cummings JL.

J Alzheimers Dis. 2019;67(1):303-313. doi: 10.3233/JAD-180595.

PMID:
30636738
49.

Computer-assisted prediction of clinical progression in the earliest stages of AD.

Rhodius-Meester HFM, Liedes H, Koikkalainen J, Wolfsgruber S, Coll-Padros N, Kornhuber J, Peters O, Jessen F, Kleineidam L, Molinuevo JL, Rami L, Teunissen CE, Barkhof F, Sikkes SAM, Wesselman LMP, Slot RER, Verfaillie SCJ, Scheltens P, Tijms BM, Lötjönen J, van der Flier WM.

Alzheimers Dement (Amst). 2018 Oct 8;10:726-736. doi: 10.1016/j.dadm.2018.09.001. eCollection 2018.

50.

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.

Lleó A, Núñez-Llaves R, Alcolea D, Chiva C, Balateu-Paños D, Colom-Cadena M, Gomez-Giro G, Muñoz L, Querol-Vilaseca M, Pegueroles J, Rami L, Lladó A, Molinuevo JL, Tainta M, Clarimón J, Spires-Jones T, Blesa R, Fortea J, Martínez-Lage P, Sánchez-Valle R, Sabidó E, Bayés À, Belbin O.

Mol Cell Proteomics. 2019 Mar;18(3):546-560. doi: 10.1074/mcp.RA118.001290. Epub 2019 Jan 3.

Supplemental Content

Loading ...
Support Center